Background: Asthmatic patients have higher microbiome diversity and an altered composition, with more Proteobacteria and less Bacteroidetes compared with healthy control subjects. Studies comparing airway inflammation and the airway microbiome are sparse, especially in subjects not receiving antiinflammatory treatment. Objective: We sought to describe the relationship between the airway microbiome and patterns of airway inflammation in steroid-free patients with asthma and healthy control subjects. Methods: Bronchoalveolar lavage fluid was collected from 23 steroid-free nonsmoking patients with asthma and 10 healthy control subjects. Bacterial DNA was extracted from and subjected to Illumina MiSeq sequencing of the 16S rDNA V4 region. Eosinophils and neutrophils in the submucosa were quantified by means of immunohistochemical identification and computerized image analysis. Induced sputum was obtained, and airway hyperresponsiveness to mannitol and fraction of exhaled nitric oxide values were measured. Relationships between airway microbial diversity and composition and inflammatory profiles were analyzed. Results: In asthmatic patients airway microbial composition was associated with airway eosinophilia and AHR to mannitol but not airway neutrophilia. The overall composition of the airway microbiome of asthmatic patients with the lowest levels of eosinophils but not asthmatic patients with the highest levels of eosinophils deviated significantly from that of healthy subjects. Asthmatic patients with the lowest levels of eosinophils had an altered bacterial abundance profile, with more Neisseria, Bacteroides, and Rothia species and less Sphingomonas, Halomonas, and Aeribacillus species compared with asthmatic patients with more eosinophils and healthy control subjects. Conclusion: The level of eosinophilic airway inflammation correlates with variations in the microbiome across asthmatic
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Until recently, the lower airways were considered a sterile environment. However, new culture-independent 16S rDNA sequencing methods have revealed that the lower airways host diverse communities of microbes. 1, 2 In 2010, Hilty et al 1 were the first to show that the microbiome of the lower airways of asthmatic patients differed significantly from that of healthy control subjects, with increased bacterial diversity, including more Proteobacteria and less Bacteroidetes.
Asthma is defined as a chronic inflammatory disease, and a type 2 immune response characterized by the presence of IL-4, IL-5, and IL-13, with IL-5 driving eosinophilic recruitment, is the most well-described type of inflammation. However, approximately half of all asthmatic patients show no signs of eosinophilic airway inflammation, 3 which is often referred to as noneosinophilic asthma (NEA). Subjects with NEA also have a T H 2-low phenotype of asthma 4 characterized by low expression of IL-13-inducible genes. The disease-driving mechanisms are less well understood in patients with NEA. However, it has repeatedly been shown that patients with NEA respond less well to inhaled corticosteroids (ICSs). 4, 5 Only a few studies have investigated the relationship between the airway microbiota and airway inflammation in asthmatic patients and only in patients with severe disease receiving high doses of ICSs, which might influence both the type of airway inflammation and the bacterial habitat. However, Green et al 6 demonstrated that colonization with known pathogenic bacteria, such as Moraxella catarrhalis or Haemophilus influenzae or members of the Streptococcus genus, in sputum was associated with increased numbers of neutrophils and increased levels of IL-8. Positive correlations between Proteobacteria and T H 17-associated gene expression have been reported, whereas airway submucosal eosinophil counts have been suggested to be negatively associated with the relative abundance of Moraxellaceae and Helicobacteraceae. 7 Thus there is a need for studies that systematically describe airway inflammation in relation to the airway microbiome, especially in subjects taking no ICSs or other anti-inflammatory treatments that might influence airway inflammation.
Based on the assumption that bacteria can drive T H 1-type inflammation and eventually neutrophil recruitment, we hypothesized that the airway microbiome would differ between steroid-free patients with asthma depending on their inflammatory status and that an altered microbiome would be expected, especially in those asthmatic patients with noneosinophilic or neutrophil-dominated disease. To test this, we performed 16S rDNA sequencing on bronchoalveolar lavage (BAL) fluid from steroid-free nonsmoking patients with asthma and healthy control subjects and compared the microbial composition with inflammatory parameters of induced sputum, BAL fluid, and airway mucosal biopsy specimens.
METHODS

Study design
This is a cross-sectional study of asthmatic patients and healthy control subjects. All participants attended the clinic 4 times a minimum of 1 day apart, with no more than 4 weeks between visits and visit 4. Measurement of airway hyperresponsiveness (AHR) to mannitol and fraction of exhaled nitric oxide (FENO) values, sputum induction, and bronchoscopy with BAL and mucosal biopsies were performed. The scientific ethics committee approved the study (H-2-2010-130), and written informed consent was obtained from all subjects before entering the study. Data were originally collected as part of a study exploring airway mast cell involvement in AHR. 8 
Participants
Inclusion criteria for asthmatic patients (n 5 23) included a history of at least 1 positive objective diagnostic test response suggestive of asthma (methacholine test [PD 20 < 8 mmol] , mannitol test [PD 15 < 635 mg], and FEV 1 reversibility to a b 2 -agonist of 12% or greater and 250 mL), current asthma symptoms (within the last 4 weeks), nonsmoking for at least the past 6 months (and < _10 pack-years), being corticosteroid free (> _3 months), and no history of other chronic lung diseases. The distribution of objective tests for asthma in which subjects were included is presented in Table I . No subjects were taking long-acting b 2 -agonists, leukotriene modifiers, or cromoglycates. Inclusion criteria for the group of healthy control subjects were as follows: no history of asthma or other chronic lung diseases, negative objective diagnostic test results suggestive of asthma, and nonsmoking for at least the past 6 months (and < _10 pack-years). Control subjects were not matched with asthmatic patients on any parameter before inclusion. All participants were without clinical airway infections for at least 6 weeks before visit 1 and throughout visit 4, but use of antibiotics for reasons other than airway infection was not recorded.
To build microbial a composition profile of the 16S rDNA V4 region, amplicon sequencing was performed on the bacterial community in BAL fluid from 23 asthmatic patients and 10 healthy control subjects, and the data were combined with measures of eosinophil and neutrophil counts in submucosal biopsy specimens and sputum, blood eosinophil counts, AHR to mannitol, and FENO values.
Lung function, FENO, AHR to mannitol, atopy, and induced sputum Lung function, FENO, and AHR to mannitol were measured in accordance with international recommendations 8 and manufacturers' guidelines. A positive mannitol test result was defined as a decrease in FEV 1 of at least 15% after inhalation of 635 mg of mannitol or less. As an index for the reactivity to inhaled mannitol, the response dose ratio (RDR) was calculated. Skin prick tests were performed, and atopy was defined as a positive skin prick test response to at least 1 aeroallergen. Induced sputum was obtained after bronchodilator pretreatment, and participants inhaled nebulized solutions of sodium chloride 3%, 4%, and 5% for 5 minutes for each solution. A minimum of 100 nonsquamous cells were counted. See the Methods section in this article's Online Repository at www.jacionline.org for further details about clinical tests.
Bronchoscopy
BAL fluid and mucosal biopsy specimens were collected after achievement of local anesthesia and sedation with intravenously administered midazolam. BAL was performed first in the left upper lobe (segments 4 and 5), installing 2 3 60 mL of NaCl. Biopsy specimens (n 5 4-8 per patient) were taken from right middle and lower lobes, immediately immersed in fixative (4% formaldehyde), and then processed for paraffin embedding. BAL fluid was centrifuged at 4000 rpm for 10 minutes, and the pellet was used for further 16S sequencing.
Immunohistochemistry
Eosinophils and neutrophils were detected by means of immunohistochemistry with antibodies (eosinophil cationic protein [EG2] and Myeloperoxidase [MPO], respectively) previously validated for use on paraffin-embedded tissue sections. 9, 10 Immunohistochemistry was performed identically and simultaneously for all subjects in an automated immunohistochemistry robot operating at room temperature (Autostainer LV-1; Dako A/S, Glostrup, Denmark). Sections stained for periostin were digitalized in an automated digital slide-scanning robot, as specified above. The generated highresolution images were then analyzed in ImageScope software (version 10.0.36.1805; Aperio Technologies, Vista, Calif). See the Methods section in this article's Online Repository for further details.
Quantification of eosinophils, neutrophils, and periostin
Stained sections were digitalized in an automated digital slide-scanning robot (Scanscope CS; Aperio Technologies). The generated high-resolution images were then analyzed in Visiopharm Integrator System (v. 4.4.4.0; Visiopharm A/S, Hørsholm, Denmark). The program detected the area of tissue (as revealed by means of hematoxylin background staining) and areas of positive immunostaining. For each leukocyte marker, a fixed threshold value for positive immunoreactivity was used to detect and quantify chromogen color and staining intensity.
A positive staining recognition algorithm was used to detect periostin staining and separate it from background staining. Periostin staining was measured, as previously done by others (ie, by measuring the mean percentage of immunoreactivity of periostin in the subepithelial region, which was defined as the region between the epithelium and muscularis mucosa or submucosal gland tissue).
DNA yield and integrity were assessed by using a Nanodrop and agarose gel electrophoresis, respectively. The PCR-based library formation was performed with 10 ng of bacterial DNA, 0.2 mmol/L of each barcoded forward and reverse primer, 0.2 mmol/L dNTPs, and 0.5 U of Phusion high-fidelity DNA polymerase (Thermo Scientific, Waltham, Mass) in a total volume of 25 mL. Specific primers and detailed sequencing methods are described in the Methods section in this article's Online Repository. 12 
Bioinformatics
The generated Fastq files were demultiplexed by using MiSeq Controller Software and trimmed for diversity spacers with biopieces (biopieces.org), mate-paired with usearch v7.0.1090, 13 and filtered with usearch-maxee 0.5. UPARSE 14 for operational taxonomic unit (OTU) clustering, as recommended. Representative sequences were classified with the Mothur v.1.25.0 wang() function 15 at the 0.8 confidence threshold. There was an average of 37,570 6 13,016 (SD) sequences per sample before and 36,923 6 12,915 (SD) sequences per sample after filtering.
Subsequent analyses were performed in R v3.1.0 software by using the metagenomeSeq, 16 phyloSeq, 17 Vegan, 18 and ggplot2 19 packages. Data were filtered for low-abundance OTUs by means of removal of OTUs present in fewer than 2 of the samples and with a relative abundance across all samples of 0.005% or less for all but a-diversity analysis. The Shannon diversity index (a-diversity), which accounts for species richness and evenness, was computed with the phyloSeq package plot_richness() function. The Whittaker index (b-diversity), which is a measure of the dissimilarity between communities at different sites, was used to calculate the b-diversity within the Vegan package.
Statistical analysis
Eosinophilia and neutrophilia are expressed as percentages of immunoreactivity to EG2 or MPO, respectively (ie, the area of positive immunostaining divided by the combined area of tissue and positive immunostaining). All biopsy measures are expressed as medians (interquartile ranges). Based on median EG2 and MPO values, asthmatic patients were divided into eosinophil-high and eosinophil-low and neutrophil-high and neutrophil-low groups. Basic characteristics were calculated in SPSS software (version 22; SPSS, Chicago, Ill). GraphPad Prism 6 software was used to plot and calculate significant differences in a-and b-diversity by using the Kruskal-Wallis test followed by Dunn corrections for multiple comparisons. Correlations between eosinophils and bacterial OTUs were calculated by using cor.test() in R software with Spearman correlations. Normalized counts for the significantly different abundant bacteria between the eosinophil-high and eosinophil-low groups were also plotted with GraphPad Prism 6 software and retested for significance by using Mann-Whitney tests.
RESULTS
Data on airway microbiota and airway inflammation in the submucosa were available for 23 asthmatic patients and 10 healthy control subjects. Based on the median values of EG2 and MPO submucosal staining activity, respectively, asthmatic patients were subdivided into eosinophil-low, eosinophil-high, neutrophil-low, and neutrophil-high groups. Asthmatic patients in the eosinophil-high group had more sputum and BAL eosinophils, higher FENO values, more AHR to mannitol, and a higher Asthma Control Questionnaire score compared with asthmatic patients in the eosinophil-low group (Table I) . Correlations between measures of eosinophilia have been reported elsewhere. 8 Measures of periostin staining activity in submucosa were significantly higher in patients with eosinophil-high asthma compared with healthy control subjects but not between patients with eosinophil-high versus those with eosinophil-low asthma and patients with eosinophil-low asthma versus healthy control subjects, respectively (Table I) . Submucosal eosinophilia, but not neutrophilia, is correlated with diversity and community composition in the lower airways microbiome
The a-diversity in the BAL microbiome in patients with eosinophil-low asthma compared with healthy control subjects was higher, indicating patients with eosinophil-low asthma host more different bacteria in BAL fluid compared with healthy subjects. bDiversity was lower in patients with eosinophil-low asthma compared with that in both healthy subjects and patients with eosinophil-high asthma (Fig 1, A) , which indicate the abundance profile is more uniform in patients with eosinophil-low asthma. There was no difference in a-diversity between groups stratified for neutrophils in the submucosa, whereas patients with neutrophil-high asthma had lower b-diversity compared with patients with neutrophil-low asthma and healthy control subjects (Fig 1, B) .
The differences in microbiome composition between patients with eosinophil-low asthma and those with eosinophil-high asthma were visualized with principal coordinate analysis (PCoA) plots (Fig 2) and confirmed with permutational multivariate ANOVA. A separation between the healthy subjects and patients with eosinophil-low asthma (P < .05), as well as between patients with eosinophil-high and eosinophil-low asthma (P < .01) but not healthy subjects and patients with eosinophil-high asthma (P 5 .10), was observed (Fig 2, A) . An environmental fit of EG2 and MPO levels in the submucosa, RDR to mannitol, and the 5% most extreme bacterial vectors are shown in When plotting only asthmatic patients, sample separation could be observed in relation to the level of EG2 staining activity in the submucosa (P <.01; Fig 2, B) and mannitol reactivity (P 5.01) but not to the level of MPO staining activity in the submucosa (P 5.12). An environmental fit of the variables confirmed that EG2 levels (P 5 .001), mannitol reactivity (P < .01), sputum and BAL eosinophil counts (P <.01 and P <.05), and FENO values (P <.05), but not submucosal, BAL, or sputum neutrophil counts (P 5 .11, P 5 .64, and P 5 .11), significantly explained separation of microbiota.
Relative abundance of bacteria in the lower airways in healthy subjects and steroid-free patients with eosinophil-high versus eosinophil-low asthma Taxa summary plots of the 20 most abundant bacterial genera in healthy control subjects and asthmatic patients are presented in FIG 1. a-Diversity (A) and b-diversity (B) in the BAL microbiome as stratified by healthy subjects (green) or patients with either eosinophil-high or neutrophil-high asthma (blue) or patients with eosinophil-low or neutrophil-low asthma (red) in the submucosa. a-Diversity was calculated as the Shannon index (a measure of species richness and evenness), and b-diversity was calculated by using the Whittaker index (a measure of dissimilarity between communities). Significant differences between the groups were tested by using a Kruskal-Wallis test with Dunn corrections for multiple comparisons and indicated by a horizontal bar between the 2 columns, with stars denoting the P values. Corrected P values without significance are given for comparisons in which the P value was close to .05. +P < .05, ++P < .01, and +++P < .001, respectively. Among bacterial genera with a prevalence of 100% in the samples, 14 bacterial genera differed significantly in relative abundance between healthy subjects and asthmatic patients with either eosinophil-low or eosinophil-high disease (Table II) . Eight of these (Aeribacillus, Halomonas, Neisseria, Nesterenkonia, Rothia, Shewanella, Sphingomonas, and Virgibacillus species) exhibited significantly different relative abundances between both healthy subjects and patients with eosinophil-low asthma and patients with eosinophil-high versus those with eosinophil-low asthma. Only 2 bacterial genera differed significantly in relative abundance between healthy subjects and patients with eosinophil-high asthma (Blautia and Lachnospiracea Incerta Sedis).
Six bacterial genera were significantly more abundant in patients with eosinophil-low compared with those with eosinophil-high asthma (Fig 4, A) , whereas 8 bacterial genera were significantly less abundant (Fig 4, B) . The full phylogeny of these bacterial genera and their candidate species are shown in Table III .
Within the group of gram-negative bacteria, the most abundant genera were Neisseria, which exhibited significantly higher relative abundance in eosinophil-low compared with eosinophil-high asthma, and Halomonas, which exhibited significantly lower relative abundance in eosinophil-low compared with eosinophil-high asthma. The representative sequence of the Neisseria OTU was identified as Neisseria subflava by building a phylogenetic tree with Neisseria sequences from the Ribosomal Database Project database. For Halomonas species, it was not possible to unequivocally suggest a candidate species among Halomonas korlensis, Halomonas daqiaonensis, and Halomonas cerina by using the V4 16S rDNA region.
Of the most abundant gram-positive bacteria, Aeribacillus species was present in significantly lower and Actinomyces and Rothia were found in significantly higher relative abundance in patients with eosinophil-low versus those with eosinophil-high asthma. The candidate species for Aeribacillus, Aeribacillus pallidus, is the only known species in this genus.
A similar analysis was carried out for samples stratified by neutrophil counts in the submucosa, which revealed very few significant differences in the abundance of bacteria, and none of these showed 100% prevalence among the samples (see Tables E1  and E2 in this article's Online Repository at www.jacionline.org). PCoA plots using weighted UniFrac distances in the BAL microbiome. A, PCoA plot with healthy control subjects, patients with eosinophil-high asthma, and patients with eosinophil-low asthma. Analysis of similarity (ANOSIM) conducted on each pairwise comparison and Holm corrected for the number of pairwise comparisons showed a significant difference in microbiome composition between healthy subjects versus patients with eosinophil-low asthma (P < .05) and patients with eosinophil-high asthma versus patients with eosinophil-low asthma (P < .01) but not between healthy control subjects and patients with eosinophil-high asthma (P 5 .10). Ellipses represent the 0.95 confidence level. Environmental variables and individual bacterial abundances were fitted onto the ordination and displayed as vectors. The degree of submucosal eosinophilia (P < .01, R 2 5 0.26) and mannitol reactivity (P 5 .01, R 2 5 0.20) were major drivers explaining the separation. Submucosal neutrophilia (P 5 .12, R 2 5 0.12) was not significant but is shown in the plot. For the bacterial vectors, only the 5% most extreme correlations are shown. The length and direction of a vector represents the correlation between the vector and the microbiome data. B, PCoA plot with asthmatic patients only colored according to submucosal eosinophilia. ANOSIM analysis confirmed the significant difference in microbiome composition between patients with eosinophil-high asthma and those with eosinophil-low asthma (P < .01). Ellipses represent the 0.95 confidence level. Environmental variables and individual bacterial abundances were fitted onto the ordination and displayed as vectors. For analysis of the asthmatic patients, the degree of submucosal eosinophilia (P < .05, R 2 5 0.28) and mannitol reactivity (P < .01, R 2 5 0.38) were major drivers of separation. The length of the vector represents the correlation between the vector and the microbiome data. Submucosal neutrophilia (P 5 .51, R 2 5 0.07) was not significant but is shown in the plot. For the bacterial vectors, only the 5% most extreme vectors are shown. The length and direction of a vector represents the correlation between the vector and the microbiome data.
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Metagenome prediction from 16S rDNA data reveals functional differences in patients with eosinophil-low and those with eosinophil-high asthma 16S rDNA amplicon data were supplemented with genomic data by using PICRUSt. Briefly, a repository of full genomesequenced bacteria was searched by using the representative 16S rDNA sequences, and the most likely genome content of each bacteria found in the sample was selected and multiplied by the original abundance to produce a quantitative estimate of the gene content of the sample. Genes from different bacteria likely to perform the same function have been grouped into KEGG orthologues (KO) by the Kyoto Encyclopedia of Genes and Genomes (KEGG). Differentially abundant KOs were screened by using the Bonferroni-corrected Wilcoxon rank sum test for differences between patients with eosinophil-high and eosinophillow asthma, revealing 12 different KOs (see Fig E2 in this article' s Online Repository at www.jacionline.org). No differences were found between patients with neutrophil-high and those with neutrophil-low asthma after adjustment for multiple testing.
Of particular interest was nitric oxide (NO) synthase (K00491, P < .05). Linear regression of FENO against the predicted abundance of NO synthase showed a statistically significant correlation that could explain 25% of the variation in FENO measurements (see Fig E3 in this article' s Online Repository at www.jacionline.org). Adjusting for blood eosinophil counts still produced a significant increase in FENO values (P <.05), with a ratio of F scores (eosinophils/NO synthase) at 2.24, suggesting that blood eosinophil counts explain roughly twice the amount of variance compared with NO synthase linked to airway microbiota.
Other potentially interesting enzymes that came out significantly in the analysis were protein disulfide isomerase and glutamate racemase, the latter involved in peptidoglycan production, suggesting differences in the gram-positive/negative ratio. The fraction of gram-positive bacteria was found to be positively correlated with eosinophil counts in submucosa (Pearson's correlation coefficient: 0.49, P < .05). Other genes seemed to be merely household genes, such as DNA polymerase.
Sensitivity analysis
To test the robustness of the association between eosinophilic airway inflammation and the airway microbiota, we performed a number of additional analyses. Fig E4 in this article' s Online Repository at www.jacionline.org shows P values for varying diversity cut points in subjects stratified based on EG2 or MPO levels, which confirm that b-diversity (and, to a lesser extent, a-diversity) significantly differs over a range of cut points in subjects stratified based on EG2 but not MPO values. The findings were further substantiated by using sputum eosinophils instead of EG2, confirming a lower b-diversity in asthmatic patients with the lowest numbers of sputum eosinophils compared with both asthmatic patients with the highest levels of eosinophils and healthy control subjects (see Fig E5 in this article' s Online Repository at www.jacionline.org). A similar separation of subjects in a PCoA plot was also seen by using sputum eosinophil counts instead of EG2 values (data not shown).
Because most of the variation (62.7%) in the microbiota was explained on the primary axis of the PCoA plot in Fig 2, A (but with 3 potential outliers in the group of healthy control subjects), we wanted to determine which bacteria explained most of the variation along the axis. The same bacteria that were identified in Table II were also the ones that contributed the most in explaining the variation along the primary axis (Fig 2, A) and remained so considering only the asthmatic patients (Fig 2, B) . To examine whether disease status (asthmatic patients vs healthy control subjects) contributed in explaining the variation along the primary axis, both disease status and eosinophil counts were fitted against the primary axis. Although disease status did not contribute to the separation along the primary axis (goodness of fit 5 0.07, P 5.13), the level of EG2 contributed to the separation (goodness of fit 5 0.32, P < .01).
Finally, to further characterize the association between a type 2 inflammatory response and airway microbiota, we subdivided asthmatic patients into 2 equal groups based on the median level of periostin staining activity in the submucosa (primarily representing an IL-13 pathway) as opposed to eosinophilia (representing an IL-5 pathway). No separation of the samples was observed when submucosal periostin was used as an explanatory variable in a PCoA plot looking at differences in the airway microbiome (see Fig E6 in this article' s Online Repository at www.jacionline.org). No difference was found in a-diversity, whereas the group of asthmatic patients with the lowest levels of periostin had lower b-diversity (see Fig E7 in this article' s Online Repository at www.jacionline.org).
DISCUSSION
In this study of steroid-free patients with asthma and healthy control subjects, the microbiome in BAL samples differed in accordance with eosinophilic, but not neutrophilic, airway inflammation. Patients with eosinophil-low asthma had lower b-diversity compared with patients with eosinophilic-high asthma and healthy controls, and had a higher a-diversity compared with healthy controls, which means the lung microbial community in patients with eosinophil-low asthma harbors a more diverse microbiota, although with less variation between subjects. Differences in relative abundance of specific bacteria were identified between both healthy subjects and both patients with eosinophil-low and those with eosinophil-high asthma but also between patients with either eosinophil-low or eosinophilhigh asthma. The results substantiate previous findings linking asthma with microbiota diversity and suggest that microbial diversity is associated with eosinophilic airway inflammation.
Existing data on the airway microbiome and airway inflammation are inconsistent. Green et al 6 identified increased levels of neutrophils and IL-8 in patients with severe asthma colonized with Haemophilus or Streptococcus species in sputum, whereas Huang et al 2 collected airway microbiota from subjects with suboptimally controlled asthma but found no association with neither eosinophils nor neutrophils in sputum. Another study by Huang et al 7 examined the microbiome in brush biopsy specimens from 40 patients with severe asthma and found that airway submucosal eosinophil counts were predominantly negatively associated with the relative abundance of bacteria, such as Moraxellaceae and Helicobacteraceae, whereas no association with measures of neutrophilia was identified. Bacterial diversity and specific strains of bacteria have also been related to inflammatory and clinical markers in patients with other respiratory diseases, such as chronic obstructive pulmonary disease and cystic fibrosis, [20] [21] [22] and at the moment, it seems that an increased proportion of Proteobacteria in subject with disease is the consistent 
FIG 4.
Abundance of bacterial genera in BAL fluid from patients with eosinophil-high asthma or patients with eosinophil-low asthma. The expectation-maximization algorithm was run on normalized count data for all OTUs in each sample to identify genera that differed significantly in abundance in BAL fluid from asthmatic patients with either high or low submucosal eosinophilia. Only genera with 100% prevalence in both groups are shown. Normalized counts of all OTUs belonging to a specific bacterial genus were summed within each sample, and the averages and SEMs for all samples in each group (high or low) were divided into bacterial genera that were either significantly more abundant (A) or significantly less abundant (B) in patients with eosinophil-low asthma compared with those with eosinophil-high asthma. Horizontal bars between the different columns represent significant findings, with stars denoting P values. +P < .05, ++P < .01, and +++P < .001, respectively.
finding in most studies, whereas the specific genera and species identified in each study vary. The inconsistencies in these reports might be a result of differences in sampling site (sputum vs brush biopsy specimens vs BAL fluid) and measures of inflammation (sputum vs submucosa) but also the level and type of antiinflammatory treatment in the study populations. Knowledge of functional properties of specific bacterial species in relation to airway inflammation is sparse. Larsen et al 23 showed in rodents that Proteobacteria (H influenzae and M catarrhalis) compared with Bacteroidetes (Prevotella species) were able to induce higher levels of proinflammatory cytokines (eg, IL-8, TNF-a, and thymic stromal lymphopoietin) and higher airway neutrophil recruitment (but with no detectable eosinophil recruitment). Conversely, bacteria might also play a critical role in ensuring normal cellular maturation and control of allergic airway inflammation. 24 The precise role and identity of the bacteria involved in airway inflammation still remains to be established, and it even seems that phylogenetically closely related bacteria exhibit both anti-inflammatory and proinflammatory actions. 25 We identified a number of Proteobacteria that differed in abundance with the level of eosinophilia but with opposite correlations for different genera. Thus Neisseria species were negatively associated with EG2 levels in the submucosa, whereas Halomonas and Sphingomonas species were positively correlated. This emphasizes the complex relationships between airway inflammation and microbiota and calls for intervention studies that allow conclusions on possible causal relations.
One of the genera that was closely associated with the level of EG2 was the gram-negative Neisseria subflava, which were significantly more abundant in patients with eosinophil-low asthma compared with those with eosinophil-high asthma. Hilty et al 1 were the first to identify Neisseria species to be more The 16S V4 region sequence of the most abundant OTU within an identified genus was aligned by using MUSCLE to other known sequences within that genus downloaded from the Ribosomal Database Project. Phylogenetic tree building was performed in MEGA6 by using the maximum likelihood method based on the Tamura-Nei model to identify species candidates.
J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 2 abundant in asthmatic patients but did not report measures of airway inflammation. It has previously been shown that Neisseria species have immunomodulatory properties through membrane porins that have been established as pathogen-associated molecular pattern recognized by Toll-like receptor 2 on dendritic cells, causing increased levels of IL-6. 26 Neisseria subflava has specifically been shown to significantly increase after rhinovirus infection, 27 which further stresses the importance of evaluating not only the microbiome but also the virome in future studies.
Another genus of potential interest is Sphingomonas (also gram-negative), which was less abundant in patients with eosinophil-low asthma compared with those with eosinophilhigh asthma. Sphingomonas species have previously been associated with increased AHR to methacholine. 2 Glycolipid antigens from Sphingomonas species are believed to induce AHR in mice through activation of invariant natural killer T cells in an IL-33-dependent manner. 28, 29 In the present study AHR was significantly more prevalent in patients with eosinophil-high asthma, in whom Sphingomonas species was also more abundant. Furthermore, independent of airway eosinophilia, AHR to mannitol was found to explain a significant part of the variation in the airway microbiome. Prospective studies investigating the possible mechanisms whereby bacterial glycolipids lead to AHR would be of interest in relation to the development of improved therapies for asthma.
The subjects in this study with eosinophil-low asthma resemble in many ways subjects previously defined as having paucigranulocytic asthma or NEA. 30 NEA constitutes up to 50% of the asthmatic population, 3 but as opposed to eosinophilic asthma, the causes of NEA are poorly understood, and few treatments are targeted toward this group of patients. None of the subjects with eosinophil-low asthma had sputum eosinophil counts of 2% or greater, whereas this was the case for 8/11 subjects in the eosinophil-high asthma group. Only a few subjects (3 in the eosinophil-low group and 4 in the eosinophil-high group) had significant neutrophilia (> _61%) in sputum. It is possible that this might reflect the relatively mild disease in the subjects studied, as opposed to subjects with severe disease and a more pronounced neutrophilic inflammatory response. Finally, it needs to be stressed that the cut point between subjects with a high and low degree of inflammation in this article was solely based on the median values of EG2 and MPO in the submucosa, making the cut points clinically arbitrary. This was primarily due to the exploratory study design but also the limited number of subjects. Therefore the results cannot be related directly to specific asthma phenotypes.
Even though the overall composition of the airway microbiota showed a more clear separation between patients with eosinophillow asthma and healthy control subjects compared with patients with eosinophil-high asthma and healthy control subjects, significant differences at the genus level were identified between all groups. Based on these results, we can only speculate on any causal relation between the microbiota and airway inflammation, but as stated above, the interrelations are undoubtedly complex, with indices of bacteria being able to work in both a proinflammatory and anti-inflammatory fashion depending on the disease state of the subject and the overall microbial composition (including vira).
In conclusion, in steroid-free patients with asthma and healthy control subjects, the microbiome in BAL fluid differed in accordance with eosinophilic, but not neutrophilic, airway inflammation. Asthmatic patients with the lowest levels of EG2 in submucosa differed in microbial diversity (ie, had higher adiversity and lower b-diversity) compared with asthmatic patients with the highest levels of EG2 in the submucosa and healthy control subjects. This was mainly due to changes in bacterial abundance rather than replacement of certain taxa. Both groups of asthmatic patients (ie, eosinophil-low and eosinophil-high groups) exhibited specific alteration at the genus level, which calls for further studies that look into the causal relationship between the airway microbiota and alterations of molecular pathways in eosinophilic and noneosinophilic airway inflammation.
Clinical implications: The level of eosinophilic airway inflammation correlates with variations in microbiomes across patients with asthma. This warrants further investigation on molecular pathways involved in asthma and the relation to airway microbiota. 
METHODS
Bronchial provocation tests
Dry powder inhaled mannitol (Osmohale; Pharmaxis, Frenchs Forest, Australia) was administered in increasing doses 1 minute apart (0, 5, 10, 20, 40, 80, 160, 160, and 160 mg), and FEV 1 was recorded after each dose. E3 The challenge was stopped at a decrease in FEV 1 of 15% or greater from baseline value (0-mg placebo capsule) or when the maximum cumulative dose of 635 mg had been administered. A positive test result was defined as a decrease in FEV 1 of at least 15% after inhalation of 635 mg of mannitol or less. Shortacting b 2 -agonists were paused at least 8 hours before the 2 challenges.
As an index for the reactivity to inhaled mannitol and methacholine, the RDR was calculated. This is defined as the percentage decrease in FEV 1 after the last dose administered divided by the final cumulative dose in milligrams or micromoles. RDR values were log transformed (subjects with no reduction or a negative reduction in FEV 1 after a bronchoprovocation testing were set to an arbitrary 0.1 L reduction in FEV 1 ).
Immunohistochemistry
Simultaneous detection of eosinophils and neutrophils was done, as previously described, E4,E5 by using a double-staining kit (K5361, Dako A/S), according to the manufacturer's instructions. Before automated immunohistochemistry, the sections were first incubated at 608C for 30 minutes and then pretreated (deparaffinized, rehydrated, and antigen retrieved) at pH 6.0 by using a PT Link (Dako A/S), according to the manufacturer's instructions. Immunohistochemical staining was then performed by first quenching endogenous peroxidase and alkaline phosphatase with a dual endogenous enzyme-blocking reagent (K5361, Dako A/S) for 10 minutes. Next, sections were treated with antibodies to detect chymase (CC1; Novocastra, Newcastle upon Tyne, United Kingdom; concentration 1:100) or eosinophils (EG2; Pharmacia-Upjohn Diagnostics AB, Sweden; concentration 1:1000) for 60 minutes. Sections were then incubated with a dextran polymer reagent containing both secondary anti-mouse and anti-rabbit antibodies and peroxidase molecules (K5361, Dako A/S) for 30 minutes. After this step, sections were incubated with the nonpermeable chromogen DAB (K5361, Dako A/S) for 10 minutes. Next, a double-staining blocking solution (K5361, Dako A/S) was added (5 minutes) to denature residual secondary antibodies on the dextran polymer to avoid cross-reactivity with the second primary antibody. After this, sections were treated with antibodies to detect tryptase (G3; Chemicon, Temecula, Calif; concentration 1:10,000) or neutrophils (MPO, A0398; Dako A/S; concentration 1:20,000) for 60 minutes. Next, a dextran polymer reagent containing secondary anti-mouse and anti-rabbit antibodies (K5361, Dako A/S) was added (10 minutes), followed by incubation with a polymer reagent containing alkaline phosphatase (K5361, Dako A/S) for 30 minutes. Lastly, sections were incubated with a permanent red chromogen solution (K5361, Dako A/S) for 10 minutes. Between the aforementioned steps, sections were washed with buffer solution (S3006, Dako A/S) or distilled water, according to the manufacturer's recommendations. Background staining was visualized with hematoxylin, and sections were mounted with PERTEX Mounting Medium (Histolab Products AB, Gothenburg, Sweden).
Staining of periostin
Sections were first incubated at 608C and pretreated (deparaffinized, rehydrated, and antigen retrieved) at pH 6.0, as described above. Immunohistochemical staining was then performed by using a single-staining kit from Dako (K8010, Dako). In brief, endogenous peroxidase activity was first quenched by using a peroxidase blocking solution (K8010, Dako). Next, sections were incubated with a rabbit polyclonal antibody against periostin (Ab79946; Abcam, Cambridge, Mass) at a concentration of 1:15,000 for 60 minutes. Sections were then treated with a dextran polymer reagent containing secondary anti-mouse and anti-rabbit antibodies and peroxidase molecules (K8010, Dako) for 30 minutes. After this, sections were incubated with nonpermeable chromogen DAB (K8010, Dako) for 10 minutes. Between the aforementioned steps, sections were washed with buffer solution (K8807) or distilled water, according to the manufacturer's recommendations. Background staining was visualized with hematoxylin, and sections were mounted with PERTEX Mounting Medium (Histolab Products).
16S Sequencing
To target the 16S rRNA gene's variable region 4 (V4), a forward primer 515F (59 AATGATACGGCGACCACCGAGATCTACACNNNNNNNN TATGGTAATTGTGTGCCAGCMGCCGCGGTAA 39) and a reverse primer 806R (59 CAAGCAGAAGACGGCATACGAGAT NNNNNNNNNNNNAG TCAGTCAGCCGGACTACHVGGGTWTCTAAT 39, where N indicates the nucleotides of the barcode sequence) were used, both with Illumina adaptor sequences in the 59 end (Illumina, San Diego, Calif). E6 Cycling conditions were as follows: 988C for 30 seconds followed by 35 cycles of 988C for 5 seconds, 568C for 20 seconds, and 708C for 20 seconds. PCR products were purified and normalized to 1 to 2 ng/mL by using the SequalPrep Normalization Plate Kit (Life Technologies Europe). Subsequently, samples were pooled (2 mL of each sample) and quantified by using a KAPA Library Quantification Kit (KAPA Biosystems, Wilmington, Mass) on a Stratagene Mx3000 (Agilent Technologies, Glostrup, Denmark). 6.65 pM library and 0.35 pM PhiX Control v3 (Illumina) were sequenced by using an Illumina MiSeq V2 PE500 cartridge (500 cycles) on an Illumina MiSeq.
Bioinformatics
Environmental fit of variables was performed in the Vegan package by fitting environmental factors and vectors onto a Bray dissimilarity ordination of the abundance data. Variables were considered significantly correlated with axes at a P value of less than .05.
PCoAwas performed in phyloSeq by using weighted UniFrac distances as a similarity index, projecting similarities into a 2-dimensional visualization. The result was visualized with ggplot2 stat_ellipse(), with ellipses representing the 95% confidence level of the multivariate Student t distribution. Significant separation of the sample groups was tested by using ANOSIM and Holm adjusted for the number of pairwise comparisons. E7 For identification of significantly different bacterial genera, metagenomeSeq was used. The eff option was set to 0.5 to exclude OTUs with low effective sample sizes.
Phylogenetic trees for candidate species identification were built in MEGA6 E8 by using type strains from the Ribosomal Database Project E9 from the same genus with MUSCLE sequence alignment E10 and phylogenetic tree building by using the maximum likelihood method based on the TamuraNei model E11 performed in MEGA v6.06.
FIG E1.
A, PCoA plot with healthy control subjects, patients with neutrophil-high asthma, and patients with neutrophil-low asthma. ANOSIM for the neutrophilic plot shows no significant difference between any of the groups: healthy control subjects versus patients with neutrophil-low asthma (P 5 .27), patients with neutrophil-high asthma versus patients with neutrophil-low asthma (P 5 .27), and healthy control subjects versus patients with neutrophil-high asthma (P 5 .19). Ellipses represent the 0.95 confidence level. B, PCoA plot with asthmatic patients only colored based on neutrophil-high or neutrophil-low asthma. ANOSIM analysis showed no separation of the samples because of submucosal neutrophilia (P 5 .12). Ellipses represent the 0.95 confidence level.
FIG E2
. KEGG orthologues that differed in abundance between patients with eosinophil-high asthma and those with eosinophil-low asthma.
FIG E3.
Correlation between measured FENO values and normalized abundance of the NO synthase KEGG orthologue.
FIG E5
. a-Diversity and b-diversity in BAL microbiomes according to sputum eosinophilic and neutrophilic inflammation. a-Diversity and b-diversity in the BAL microbiome as stratified by healthy subjects (green), patients with eosinophil-high asthma (blue), or patients with eosinophil-low asthma (red) in sputum are shown. a-Diversity was calculated as the Shannon index (a measure of species richness and evenness), and b-diversity was calculated by using the Whittaker index (a measure of the dissimilarity between communities). Significant differences between the groups were tested by using a Kruskal-Wallis test with Dunn corrections for multiple comparisons and indicated by a horizontal bar between the 2 columns, with stars denoting P values. Corrected P values without significance are presented for comparisons in which the P value was close to .05. +P < .05, ++P < .01, and +++P < .001, respectively.
FIG E6.
PCoA plot with asthmatic patients only colored according to submucosal periostin staining intensity. ANOSIM analysis showed no separation of the samples because of submucosal periostin (P 5 .26). Ellipses represent the 0.95 confidence level.
FIG E7
. a-Diversity and b-diversity in the BAL microbiomes according to the level of periostin staining activity in submucosa. a-Diversity and b-diversity in the BAL microbiome as stratified by healthy subjects (green), patients with periostin-high asthma (blue), or patients with periostin-low asthma (red) in sputum are shown. a-Diversity was calculated as the Shannon index (a measure of species richness and evenness), and b-diversity was calculated by using the Whittaker index (a measure of the dissimilarity between communities). Significant differences between the groups were tested by using a Kruskal-Wallis test with Dunn corrections for multiple comparisons and indicated by a horizontal bar between the 2 columns, with stars denoting P values. Corrected P values without significance are given for comparisons in which the P value was close to .05. ++P < .01. 
